The findings are preliminary since 60 patients began the study and 17 completed it. Despite the long recruitment period and multiple study sites, participation was limited by the low incidence of pre-psychotic, or ‘prodromal,’ symptoms in the general population.” (Science Daily)
The study was co-funded by the NIMH and Eli Lily, the manufacturer of the antipsychotic drug used in the study. This study seems to support the notion that early detection and treatment halts disease progression. However, the low completion rate among recruited subjects prompts the obvious question — is there some correlation between the potential for early stabilization and the wherewithal to hang in there with the study. Are the counterexamples simply washing out?
